Free Trial

Merck KGaA (OTCMKTS:MKGAF) Share Price Passes Above Fifty Day Moving Average - Here's What Happened

Merck KGaA logo with Medical background

Key Points

  • Merck KGaA's stock price has surpassed its 50-day moving average of $129.96, reaching a high of $141.90 during trading.
  • The company has a market capitalization of $18.34 billion and a debt-to-equity ratio of 0.27, indicating a relatively low level of debt.
  • Merck KGaA operates in the fields of Life Science, Healthcare, and Electronics, providing tools and equipment mainly for biotech and pharmaceutical sectors.
  • Five stocks to consider instead of Merck KGaA.

Shares of Merck KGaA (OTCMKTS:MKGAF - Get Free Report) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $129.96 and traded as high as $141.90. Merck KGaA shares last traded at $141.90, with a volume of 28 shares trading hands.

Merck KGaA Trading Up 1.6%

The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27. The firm has a market cap of $18.34 billion, a price-to-earnings ratio of 21.66 and a beta of 0.96. The business has a 50 day moving average price of $129.96 and a 200-day moving average price of $132.23.

About Merck KGaA

(Get Free Report)

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Merck KGaA Right Now?

Before you consider Merck KGaA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck KGaA wasn't on the list.

While Merck KGaA currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report
Like this article? Share it with a colleague.